Free Submission Public Relations &
Deutsch English


New Market Report Now Available: Migraine - Pipeline Review, H1 2013

Print article Print article
2013-04-01 10:29:46 - Fast Market Research recommends "Migraine - Pipeline Review, H1 2013" from Global Markets Direct, now available

Global Markets Direct's, 'Migraine - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. Migraine - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Full Report Details at



* A snapshot of the global therapeutic scenario for Migraine.
* A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Migraine pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Migraine.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Migraine Overview
Therapeutics Development
An Overview of Pipeline Products for Migraine
Migraine Therapeutics under Development by Companies
Migraine Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Migraine Therapeutics - Products under Development by Companies
Migraine Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Migraine Therapeutics Development
Bristol-Myers Squibb Company
Amgen Inc.
BioDelivery Sciences International, Inc.
Merck & Co., Inc.
Vectura Group plc
Alexza Pharmaceuticals, Inc.
Biofrontera AG
Novartis AG
Axcan Pharma Inc.
Dr. Reddy's Laboratories Limited
Teva Pharmaceutical Industries Limited
Zosano Pharma, Inc.
Capnia, Inc.
Revance Therapeutics, Inc.
IntelGenx Technologies Corp.
Lupin Limited
Paladin Labs Inc.
MAP Pharmaceuticals, Inc.
Genizon BioSciences, Inc.
Choongwae Pharma Corp
Orexo AB
D-Pharm Ltd.
Physica Pharma
MIKA Pharma GmbH
Ache Laboratorios Farmaceuticos S/A
Alder Biopharmaceuticals Inc.
Global Health Ventures Inc.
CoLucid Pharmaceuticals, Inc.
Charleston Laboratories, Inc.
Pantarhei Bioscience BV
NeurAxon, Inc.
Monosol Rx, LLC
Shin Nippon Biomedical Laboratories, Ltd.
Winston Pharmaceuticals, Inc.
Proreo Pharma AG
Heptares Therapeutics Ltd.
iCeutica, Inc.
Migraine - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AZ-104 - Drug Profile
dihydroergotamine mesylate - Drug Profile
dihydroergotamine mesylate - Drug Profile
dihydroergotamine mesylate - Drug Profile
propranolol hydrochloride - Drug Profile
BF-1 - Drug Profile
MK-49 - Drug Profile
sumatriptan succinate - Drug Profile
PHY-303 - Drug Profile
OX-641 - Drug Profile
E-4 - Drug Profile
rizatriptan benzoate - Drug Profile
RT-001 - Drug Profile
MT-400 - Drug Profile
NXN-188 - Drug Profile
NXN-462 - Drug Profile
nNOS/NET - Drug Profile
VR-147 - Drug Profile
Nasal Carbon Dioxide - Drug Profile
LLL-2011 - Drug Profile
CWF-0902 - Drug Profile
CWF-0808 - Drug Profile
DP-VPA - Drug Profile
BGG-492 - Drug Profile
LY-2951742 - Drug Profile
lasmiditan - Drug Profile
Longevity Program - Drug Profile
DR-105 - Drug Profile
filorexant - Drug Profile
doxepin - Drug Profile
Chemical Library Focussed On The Central Nervous System - Drug Profile
RHB-103 - Drug Profile
R-101 - Drug Profile
(naproxen sodium + naratriptan hydrochloride) - Drug Profile
BMS-927711 - Drug Profile
sumatriptan - Drug Profile
ALD-403 - Drug Profile
AP-1531 - Drug Profile
INT-1202 - Drug Profile
IO-1205 - Drug Profile
MK-1602 - Drug Profile

Full Table of Contents is available at:

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact